Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep Ltd is advancing its product candidate, eftilagimod alfa (efti), through a registrational Phase three clinical trial for first-line non-small cell lung cancer, which has shown promising efficacy by increasing the objective response rate (ORR) by 22.2% in patients with low tumor proportion scores. The company's robust patent portfolio and the ease of combining efti with existing therapies create significant opportunities for expanding its product offerings and strengthening its market position. With a diversified pipeline addressing various cancers and autoimmune diseases, Immutep's strategic development efforts potentially enhance its long-term financial prospects.

Bears say

Immutep's outlook is negatively impacted by the underwhelming clinical results from its lead product candidate, eftilagimod alfa (efti), which has led to a reduced probability of success in treating non-small cell lung cancer ( NSCLC) to just 30%. The overall efficacy results from the company's INSIGHT-003 trial are expected to be poorer than historical benchmarks, as the study includes a higher proportion of patients with low tumor mutational burden (TPS<1%), likely driving down efficacy outcomes. Moreover, the mixed results of LAG-3 antagonists in lung cancer and their perception as non-practice changing add to investor concerns regarding the future viability of Immutep's product portfolio.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.